Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Similar documents
JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

Hypertension Update Clinical Controversies Regarding Age and Race

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

Blood Pressure Targets: Where are We Now?

2014 HYPERTENSION GUIDELINES

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

Long-Term Care Updates

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017

Objectives. Describe results and implications of recent landmark hypertension trials

Managing Hypertension in 2016

The JNC 8 Guidelines: A Clinical Review

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

T. Suithichaiyakul Cardiomed Chula

Preventing and Treating High Blood Pressure

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

Modern Management of Hypertension

Hypertension Management: A Moving Target

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)

ADVANCES IN MANAGEMENT OF HYPERTENSION

Don t let the pressure get to you:

Modern Management of Hypertension: Where Do We Draw the Line?

Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?

Recent Hypertension Guidelines

2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016

Chapman University Digital Commons. Chapman University. Michael S. Kelly Chapman University,

Update on Current Trends in Hypertension Management

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

ADVANCES IN MANAGEMENT OF HYPERTENSION

Hypertension JNC 8 (2014)

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University

What s In the New Hypertension Guidelines?

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?

Treatment of Hypertension

Jared Moore, MD, FACP

Dr. Khan Abul Kalam Azad Associate Professor Department of Medicine SZRMC, Bogra

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Implementation of JNC- 8 Hypertension Recommendations: Combining evidence and value-based practice strategies for accountable care

Antihypertensive Trial Design ALLHAT

Hypertension Management: Making Sense of Guidelines and Therapy Options for the Elderly

TIP. Documentation and coding guide. Disease definitions* Prevalence and statistics associated with HTN**

Hypertension Controversies: SPRINTing to New Goals

The Latest Generation of Clinical

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

Treating Hypertension in Individuals with Diabetes

The underestimated risk of

HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS

Hypertension Update 2009

How clinically important are the results of the large trials in hypertension?

By Prof. Khaled El-Rabat

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Renal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Hypertension (JNC-8)

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

Supplementary Online Content

Hypertension Management Controversies in the Elderly Patient

Hypertension and Cardiovascular Disease

Preventing the cardiovascular complications of hypertension

Adult Hypertension Clinical Practice Guidelines

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi

Egyptian Hypertension Guidelines

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.

Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine

Setting The setting was primary care. The economic study was carried out in the UK and the USA.

ABSTRACT. Special Communication February 5, 2014

Randomized Design of ALLHAT BP Trial

Antihypertensive Combinations

Management of High Blood Pressure in Adults

Difficult to Treat Hypertension

Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London

Hypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

Large therapeutic studies in elderly patients with hypertension

EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION

Hypertension Pharmacotherapy: A Practical Approach

Treating Hypertension in 2018: What Makes the Most Sense Today?

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland

BLOOD PRESSURE-LOWERING TREATMENT

47 Hypertension in Elderly

Disclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012

Blood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial

See Important Reminder at the end of this policy for important regulatory and legal information.

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

Clinical Review & Education. Special Communication

Reframe the Paradigm of Hypertension treatment Focus on Diabetes

Blood Pressure Control in the Elderly How High Should You Go?

Key Words: losartan, hypertension, blood pressure, cardiovascular disease, observational study

The State of Hypertension in NZ in 2010 personal view

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM

Transcription:

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Objectives Review the Eighth Joint National Committee (JNC 8) guideline recommendations for management of high blood pressure Discuss major differences between JNC 7 and JNC 8 guidelines

JNC 8 Evidence-based recommendations for the treatment of hypertension including: Treatment thresholds Treatment goals Medications Evidence drawn from randomized controlled trials Recommendations meet clinical needs for most patients but are not a substitute for clinical judgment

Recommendations 1. In the general population aged 60 years, initiate treatment at BP 150/90 and treat to a goal of <150/90 Corollary Recommendation: If current treatment results in a lower achieved systolic blood pressure (SBP) (e.g. <140) and treatment is well tolerated without adverse effects, treatment does not need to be adjusted

Treatment of Hypertension in Patients 80 Years of Age and Older Treatment to a target BP <150/80 resulted in reduced risk of death from stroke, heart failure, any cardiovascular (CV) event, and all-cause mortality N Engl J Med.2008;358(18):1887-1898.

Moderate vs. Strict BP Control Study N Population Intervention Outcomes Hokkaido, et. al. 2008 (JATOS) Ogihara, et. al. 2010 (VALISH) 4418 65-85 years of age SBP 160 3260 70 and < 85 years of age SBP > 160 and DBP < 90 Strict control (SBP < 140) vs. mild control (SBP < 160 but > 140) Strict control (SBP < 140) vs. moderate control (140 to 149) No difference in incidence of cerebrovascular disease, CV disease, or renal failure between groups No difference in CV events (sudden death, fatal or nonfatal stroke or myocardial infarction (MI), death due to heart failure, other CV death, unplanned hospitalization for CV disease, and renal dysfunction) as a composite endpoint or as individual components between groups Hypertens Res.2008;31(12):2115-2127. Hypertension. 2010;56(2):196-202.

Recommendations 2. In the general population aged < 60 years, initiate treatment at diastolic blood pressure (DBP) 90 and treat to a goal DBP <90 3. In the general population aged < 60 years, initiate treatment at SBP 140 and treat to a goal SBP <140

Recommendations 4. In the general population 18 years with chronic kidney disease (CKD), initiate treatment at BP 140/90 and treat to a goal <140/90 5. In the general population 18 years with diabetes, initiate treatment at BP 140/90 and treat to a goal <140/90

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus Intensive blood pressure therapy (target SBP < 120) vs. standard therapy (SBP < 140) No difference in the primary outcome of prevention of composite outcome of nonfatal MI, nonfatal stroke, or CV death N Engl J Med.2010;362(17):1575-1585.

Recommendations 6. In the general nonblack population, including those with diabetes, initial antihypertensive treatment should include: Thiazide-type diuretic Calcium channel blocker (CCB) Angiotensin-converting enzyme inhibitor (ACEI) Angiotensin receptor blocker (ARB)

ARB vs. β-blocker in patients with hypertension and left ventricular hypertrophy (LVH) Higher rate of the primary composite outcome of CV death, MI, or stroke was seen with use of a β-blocker compared to use of an ARB Lancet. 2002;359(9311):995-1003.

Recommendations 7. In the general black population, including those with diabetes, initial antihypertensive treatment should include: Thiazide-type diuretic Calcium channel blocker (CCB) 8. In the population aged 18 years with CKD (regardless of race or diabetes status), initial (or addon) antihypertensive treatment should include and ACEI or ARB to improve kidney outcomes

Recommendations 9. If goal blood pressure is not reached within one month of treatment initiation increase the dose of the initial drug or add a second drug from the recommended classes If goal is not reached with 2 drugs add a third drug from the list provided Do NOT use ACEI or ARB together If goal is not reached using only the recommended drug classes, other drug classes may be utilized

Take Home Points In patients 60 years of age and older, goal BP < 150/90 In all other patient populations, goal BP <140/90 Four recommended initial treatment options: Thiazide-type diuretic CCB ACEI ARB If inadequate response to initial agents, add an agent from an additional drug class

References James PA, Oparil S, Carter BL, et. al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA.2014 Feb 5;311(5):507-520. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med.2008;358(18):1887-1898. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31(12):2115-2127. Ogihara T, Saruta T, Rakugi H, et al; Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in Elderly Isolated Systolic Hypertension Study. Hypertension. 2010;56(2):196-202. CushmanWC, Evans GW, Byington RP, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-1585. Dahlof B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet.2002;359(9311):995-1003.

QUESTIONS?